• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人诱导多能干细胞心肌细胞在心脏安全性评价非临床监管研究中的应用。

Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment.

机构信息

Division of Pharmacology & Toxicology, Office of Cardiology, Hematology, Endocrinology, & Nephrology, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, USA.

Division of Applied Regulatory Science, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, USA.

出版信息

Toxicol Sci. 2022 Nov 23;190(2):117-126. doi: 10.1093/toxsci/kfac095.

DOI:10.1093/toxsci/kfac095
PMID:36099065
Abstract

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a human-relevant platform for cardiac function assessment. Alternative assays using hiPSC-CMs are increasingly being employed for regulatory decision-making. A retrospective review revealed steady use of hiPSC-CM-based in vitro assays in nonclinical studies of drug-induced cardiotoxicity in regulatory submissions to the U.S. Food and Drug Administration (FDA). Most of the hiPSC-CMs data were obtained in exploratory studies and submitted as supportive evidence in concordance with other nonclinical data. Some of those studies were used to inform clinical trial design. This article provides an overview of the use of hiPSC-CMs in regulatory applications to FDA, with a focus on the integration of human-relevant in vitro data into proarrhythmic and non-proarrhythmic risk assessment. By identifying the regulatory submissions including hiPSC-CMs data, we explore their utility and discuss their limitations for predicting human cardiac safety in clinical trials. An important take-home message is that regulatory acceptance of hiPSC-CMs data is dependent on both the context of use and accurate data interpretation.

摘要

人诱导多能干细胞衍生的心肌细胞(hiPSC-CMs)为心脏功能评估提供了一个与人类相关的平台。越来越多的替代检测方法使用 hiPSC-CMs 进行监管决策。回顾性研究显示,在向美国食品和药物管理局(FDA)提交的药物诱导心脏毒性的非临床研究中,稳定地使用了基于 hiPSC-CM 的体外检测方法。大多数 hiPSC-CMs 数据是在探索性研究中获得的,并作为支持性证据与其他非临床数据一起提交。其中一些研究用于为临床试验设计提供信息。本文概述了 hiPSC-CMs 在 FDA 监管申请中的使用情况,重点是将与人相关的体外数据整合到致心律失常和非致心律失常风险评估中。通过确定包括 hiPSC-CMs 数据在内的监管提交,我们探讨了它们在预测临床试验中的人类心脏安全性方面的效用和局限性。一个重要的信息是,监管部门对 hiPSC-CMs 数据的接受程度取决于使用的背景和准确的数据解释。

相似文献

1
Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment.人诱导多能干细胞心肌细胞在心脏安全性评价非临床监管研究中的应用。
Toxicol Sci. 2022 Nov 23;190(2):117-126. doi: 10.1093/toxsci/kfac095.
2
Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.超越全面的体外致心律失常检测:利用人诱导多能干细胞衍生的心肌细胞评估与药物诱导的结构性心脏毒性相关的收缩作用。
J Appl Toxicol. 2018 Sep;38(9):1166-1176. doi: 10.1002/jat.3611. Epub 2018 Feb 27.
3
Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.使用人诱导多能干细胞衍生心肌细胞评估药物的心脏毒性:致心律失常风险和心脏肿瘤学。
Curr Pharm Biotechnol. 2020;21(9):765-772. doi: 10.2174/1389201020666190628143345.
4
Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).基于人诱导多能干细胞分化的心肌细胞(hiPSC-CMs)的慢性心脏毒性检测。
Int J Mol Sci. 2022 Mar 16;23(6):3199. doi: 10.3390/ijms23063199.
5
The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations.人诱导多能干细胞衍生心肌细胞在药物发现中的作用:管理体外安全研究的预期。
Expert Opin Drug Discov. 2020 Jun;15(6):719-729. doi: 10.1080/17460441.2020.1736549. Epub 2020 Mar 27.
6
Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.使用人诱导多能干细胞衍生的心肌细胞对新冠病毒治疗方法进行全面心脏毒性评估
Toxicol Sci. 2021 Aug 30;183(1):227-239. doi: 10.1093/toxsci/kfab079.
7
Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.电刺激对 hiPSC-CM 对经典离子通道阻滞剂反应的影响。
Toxicol Sci. 2020 Apr 1;174(2):254-265. doi: 10.1093/toxsci/kfaa010.
8
Does Enhanced Structural Maturity of hiPSC-Cardiomyocytes Better for the Detection of Drug-Induced Cardiotoxicity?hiPSC 心肌细胞的增强结构成熟度是否更有利于检测药物引起的心脏毒性?
Biomolecules. 2023 Apr 14;13(4):676. doi: 10.3390/biom13040676.
9
An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.使用人诱导多能干细胞衍生的心肌细胞的基于阻抗的方法显著改善了体内心脏毒性风险的体外预测。
Toxicol Appl Pharmacol. 2017 Aug 15;329:121-127. doi: 10.1016/j.taap.2017.05.023. Epub 2017 May 22.
10
Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.利用源自人诱导多能干细胞的三维心脏组织开发体外药物诱导的心脏毒性检测方法。
Tissue Eng Part C Methods. 2018 Jan;24(1):56-67. doi: 10.1089/ten.TEC.2017.0247. Epub 2017 Nov 17.

引用本文的文献

1
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development.验证和使用心脏NAMs进行毒性筛选和药物开发。
Int J Toxicol. 2025 Sep 9:10915818251375348. doi: 10.1177/10915818251375348.
2
Integral approach to organelle profiling in human iPSC-derived cardiomyocytes enhances cardiac safety classification of known cardiotoxic compounds.对人诱导多能干细胞衍生的心肌细胞中的细胞器进行分析的整体方法可增强已知心脏毒性化合物的心脏安全性分类。
Front Toxicol. 2025 Aug 21;7:1644119. doi: 10.3389/ftox.2025.1644119. eCollection 2025.
3
Delayed Repolarization Caused by hERG Block With Different Drug Modalities Can Be Detected in Stem Cell-Derived Cardiomyocytes: Incubation Time Matters.
在干细胞衍生的心肌细胞中可检测到不同药物模式导致的hERG阻断引起的延迟复极化:孵育时间很重要。
Clin Transl Sci. 2025 Sep;18(9):e70283. doi: 10.1111/cts.70283.
4
Validation of new AI-based classification method for in silico cardiac safety assessment of drugs following the CiPA framework.遵循CiPA框架对基于人工智能的药物计算机心脏安全性评估新分类方法的验证。
Arch Toxicol. 2025 May 22. doi: 10.1007/s00204-025-04079-z.
5
Human induced pluripotent stem cell-derived cardiomyocytes and their use in a cardiac organ-on-a-chip to assay electrophysiology, calcium and contractility.人诱导多能干细胞衍生的心肌细胞及其在心脏芯片中用于检测电生理学、钙和收缩性的应用。
Nat Protoc. 2025 Apr 7. doi: 10.1038/s41596-025-01166-4.
6
Clinical trials in-a-dish for cardiovascular medicine.在心血管医学中进行临床试验。
Eur Heart J. 2024 Oct 21;45(40):4275-4290. doi: 10.1093/eurheartj/ehae519.
7
A Method for Producing Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Leigh Syndrome Patients for Its Application in Disease Modeling and Drug Validation.从 Leigh 综合征患者中诱导产生多能干细胞衍生的心肌细胞的方法,用于疾病建模和药物验证。
Methods Mol Biol. 2024;2835:121-133. doi: 10.1007/978-1-0716-3995-5_11.
8
Advances in induced pluripotent stem cell-derived cardiac myocytes: technological breakthroughs, key discoveries and new applications.诱导多能干细胞衍生心肌细胞的研究进展:技术突破、关键发现和新应用。
J Physiol. 2024 Aug;602(16):3871-3892. doi: 10.1113/JP282562. Epub 2024 Jul 20.
9
In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.从 3D hiPSC 衍生的心脏微组织的体外到体内外推,以及基于生理学的药代动力学建模,为下一代心律失常风险评估提供信息。
Toxicol Sci. 2024 Sep 1;201(1):145-157. doi: 10.1093/toxsci/kfae079.
10
Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screening.挑战现状:一个用于机制性和与人类相关的心血管安全筛查的框架。
Front Toxicol. 2024 Mar 25;6:1352783. doi: 10.3389/ftox.2024.1352783. eCollection 2024.